The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Strategies for optimizing combinations of molecularly targeted anticancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 1×
“There have also been a number of notable failures: erlotinib (Tarceva; Genentech/Roche) and gefitinib (Iressa; AstraZeneca) with chemotherapy in lung cance”
BackgroundThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Drug Synergism: Its Detection and Applications
Tallarida, R. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29450-7 · Cited by 687
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Herbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
(2003) · PubMed · Cited by 523
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 411
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 396
Self-citationMass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005) · Modern Pathology · doi:10.1038/modpathol.3800438 · Cited by 355
Kelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8234 · Cited by 303
Jones, H. E., Goddard, L., Gee, J. M. W., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J. M., Williams, S., Wakeling, A. E., & Nicholson, R. I. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00799 · Cited by 297
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Sparano, J. A., Bernardo, P., Stephenson, P., Gradishar, W. J., Ingle, J. N., Zucker, S., & Davidson, N. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.054 · Cited by 269
Shepherd, F. A., Giaccone, G., Seymour, L., Debruyne, C., Bezjak, A., Hirsh, V., Smylie, M., Rubin, S., Martins, H., Lamont, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.108 · Cited by 262
Abd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J. A., Rampaul, R. S., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602184 · Cited by 256
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Friedman, H. S., Kokkinakis, D. M., Pluda, J., Friedman, A. H., Cokgor, I., Haglund, M. M., Ashley, D. M., Rich, J., Dolan, M. E., Pegg, A. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3570 · Cited by 213
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2215 · Cited by 191
Saltz, L. B., Lenz, H.-J., Hochster, H., Wadler, S., Hoff, P., Kemeny, N., Hollywood, E., Gonen, M., Wetherbee, S., & Chen, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3508 · Cited by 183
Self-citationHirte, H. W., Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B. E., Tu, D., Sadura, A., Brundage, M., & Seymour, L. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.020 · Cited by 152
Moore, M. J., Goldstein, D., Hamm, J. T., Figer, A., Hecht, J., Gallinger, S., Au, H., Ding, K., Christy-Bittel, J., & Parulekar, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1 · Cited by 140
Houghton, P. J., Stewart, C. F., Cheshire, P. J., Richmond, L. B., Kirstein, M. N., Poquette, C. A., Tan, M., Friedman, H. S., & Brent, T. P. (2000) · PubMed · Cited by 138
Lee, J. H., Torisu-Itakara, H., Cochran, A. J., Kadison, A. S., Huynh, Y., Morton, D. L., & Essner, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.107.11.1 · Cited by 132
Solit, D. B., She, Y., Lobo, J. M., Kris, M. G., Scher, H. I., Rosen, N. X., & Sirotnak, F. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1347 · Cited by 131
Evaluating Response to Antineoplastic Drug Combinations in Tissue Culture Models
Reynolds, C. P., & Maurer, B. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-869-2:173 · Cited by 126
Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy
Haince, J.-F., Rouleau, M., Hendzel, M. J., Masson, J., & Poirier, G. G. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.08.003 · Cited by 98
Warburton, C., Dragowska, W. H., Gelmon, K. A., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A. E., & Bally, M. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0244 · Cited by 83
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
Riccardi, R., Meco, D., Colombo, T., Ubezio, P., Zucchetti, M., Zaffaroni, M., Riccardi, A., Faircloth, G. T., Jose, J., & D’Incalci, M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0636-6 · Cited by 77
Tan, M. T., Fang, H., Tian, G., & Houghton, P. J. (2003) · Statistics in Medicine · doi:10.1002/sim.1467 · Cited by 60
Drug combinations: From laboratory to practice
Chou, T. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90018-x · Cited by 52
Genetic instability of cell lines derived from a single human small cell carcinoma of the lung
Engelholm, S. A., Vindeløv, L. L., Spang‐Thomsen, M., Brünner, N., Tommerup, N., Nielsen, M. H., & Hansen, H. H. (1985) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(85)90221-4 · Cited by 49
ErbB‐receptors expression and survival in breast carcinoma: A 15‐year follow‐up study
Bianchi, S., Palli, D., Falchetti, M., Saieva, C., Masala, G., Mancini, B., Lupi, R., Noviello, C., Omerović, J., Paglierani, M., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20535 · Cited by 41
Kirkwood, J. M., Bedikian, A. Y., Millward, M. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7506 · Cited by 33
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Metadata
- Authors
- Dancey, J. E., & Chen, H. X.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08
- Volume
- 5
- Issue
- 8
- Pages
- 649-659
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2147794687
- Cited by
- 365
- References
- 48
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.